Boundless Bio, a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) to develop therapies for oncogene amplified cancers, announced that its CEO Zachary Hornby will participate in ...

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) ...

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with ...

WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (UPB) (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.